TERANODE AWARDED PATENT ENABLES ADAPTIVE WORKFLOW
Unique Informatics Technology Improves Workflow Flexibility and Data Integration
Seattle, WA – May 1, 2006 – Teranode Corporation, the leading innovator of scientific data and workflow management software for the Life Sciences industry, today announced the U.S. Patent and Trademark Office (PTO) has issued the company U.S. Patent No. 7,010,760 B2 for a key element of TERANODE XDA. The patent protects the method and apparatus for TERANODE XDA's match rules, a feature for integrating datasets and metadata in dynamic workflow. By automating critical data integration, the match rules enable scientists to quickly and reliably understand the provenance and relationships of data within projects.
Traditional informatics solutions depend on static, predefined schemas and workflows which are brittle and often break down when scientists need to make changes to the design of an experiment. TERANODE XDA accommodates change through an adaptive schema and workflow capability without requiring error-prone, manual data management procedures or expensive reprogramming.
"TERANODE XDA is the first product to integrate process metadata, schema metadata, and instrument data as part of a workflow," said Larry Arnstein, CTO of Teranode. "The match rules technology provides new flexibility in laboratory operations, while providing unrivaled data integration. Once captured, TERANODE XDA leverages semantic web standards to unlock the true potential of the data by enabling analysis, reporting, and search across projects and disciplines."
TERANODE XDA is a powerful informatics platform that leverages existing IT infrastructure to manage scientific data and workflow. TERANODE XDA allows scientists to automate workflow, manage the lifecycle of scientific data, and unify disparate data across laboratories, improving the speed and quality of R&D projects.
About Teranode Corporation
Teranode Corporation, a venture-backed company headquartered in Seattle, Washington, is the leading innovator of scientific data and workflow management software for the Life Sciences industry. Teranode's award-winning products are used by leading pharmaceutical, biotechnology, research, and academic organizations, including Pfizer, AstraZeneca, NIH Chemical Genomics Center, MIT, and Fred Hutchinson Cancer Research Center, to improve the speed and value of experimentation in R&D and then share chemical and biological knowledge enterprise-wide. For more information, visit www.teranode.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
